Department of Radiology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan.
AJR Am J Roentgenol. 2012 Apr;198(4):914-22. doi: 10.2214/AJR.11.6515.
The purpose of this article is to evaluate the feasibility and efficacy of preoperative percutaneous transhepatic portal vein embolization with ethanol injection.
We retrospectively evaluated 143 patients who underwent percutaneous transhepatic portal vein embolization. Hypertrophy of the future liver remnant was assessed by comparing the volumetric data obtained from CT image data before and after percutaneous transhepatic portal vein embolization. The evaluation of effectiveness was based on changes in the absolute volume of the future liver remnant and the ratio of the future liver remnant to the total estimated liver volume.
Ten of 143 patients (7.0%) underwent additional embolization because of recanalization and insufficient hypertrophy of the future liver remnant. The mean increase in the ratio of the future liver remnant was 33.6% (p < 0.0001), and the mean ratio of future liver remnant to total estimated liver volume increased from 34.9% to 45.7% (p < 0.0001). Although most of the patients complained of pain after ethanol injection, they were gradually relieved of pain in a few minutes by conservative treatment. Fever (38-39°C) was reported after 47 of 151 (31.1%) percutaneous transhepatic portal vein embolization sessions and was resolved within a few days. Transient elevation of the liver transaminases was observed after the procedures and resolved within about a week. Major complications occurred in nine of 151 (6%) percutaneous transhepatic portal vein embolization sessions, but no patients developed hepatic insufficiency or severe complications precluding successful resection. One hundred twenty patients underwent hepatic resection, and two patients developed hepatic failure after surgery.
Preoperative percutaneous transhepatic portal vein embolization with ethanol is a feasible and effective procedure to obtain hypertrophy of the future liver remnant for preventing hepatic failure after hepatectomy.
本文旨在评估经皮经肝门静脉栓塞术联合乙醇注射的可行性和疗效。
我们回顾性评估了 143 例行经皮经肝门静脉栓塞术的患者。通过比较经皮经肝门静脉栓塞术前、后 CT 图像数据获得的体积数据,评估未来肝脏残块的增生程度。有效性评估基于未来肝脏残块的绝对体积变化和未来肝脏残块与总估计肝脏体积的比值。
143 例患者中有 10 例(7.0%)因未来肝脏残块再通和增生不足而进行了额外的栓塞。未来肝脏残块的比例平均增加了 33.6%(p<0.0001),未来肝脏残块与总估计肝脏体积的比值从 34.9%增加到 45.7%(p<0.0001)。虽然大多数患者在乙醇注射后会感到疼痛,但通过保守治疗,几分钟后疼痛会逐渐缓解。151 次经皮经肝门静脉栓塞术中有 47 次(31.1%)出现 38-39°C 的发热,几天后自行缓解。术后肝转氨酶短暂升高,约一周内恢复正常。151 次经皮经肝门静脉栓塞术中有 9 次(6%)发生严重并发症,但无患者发生肝功能不全或严重并发症而无法进行成功切除。120 例患者接受了肝切除术,其中 2 例术后出现肝功能衰竭。
经皮经肝门静脉栓塞术联合乙醇是一种可行且有效的方法,可以获得未来肝脏残块的增生,以预防肝切除术后肝功能衰竭。